Marché des troubles de la vessie en Asie-Pacifique – Tendances et prévisions de l’industrie jusqu’en 2029

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché des troubles de la vessie en Asie-Pacifique – Tendances et prévisions de l’industrie jusqu’en 2029

  • Pharmaceutical
  • Publish Reports
  • Sep 2022
  • Asia-Pacific
  • 350 Pages
  • Nombre de tableaux : 95
  • Nombre de figures : 35

>Marché des troubles de la vessie en Asie-Pacifique, par type (cystite, incontinence urinaire, vessie hyperactive, cystite interstitielle , cancer de la vessie), type de traitement (chirurgie, médicament, non chirurgical), utilisateur final (hôpitaux, cliniques, centres de chirurgie ambulatoire, autres), canal de distribution (direct, vente au détail) - Tendances et prévisions de l'industrie jusqu'en 2029.

Marché des troubles de la vessie en Asie-Pacifique

Analyse et perspectives du marché des troubles de la vessie en Asie-Pacifique 

Les troubles de la vessie sont un groupe de troubles qui peuvent affecter les activités quotidiennes de la vie humaine. Certains des troubles de la vessie les plus courants sont la cystite, dans laquelle la vessie est infectée et provoque une inflammation. L'incontinence urinaire, dans laquelle la vessie est perdue, la cystite interstitielle, dans laquelle la vessie se met à uriner fréquemment et impérativement, et la vessie hyperactive , dans laquelle la vessie comprime l'urine. Les troubles de la vessie peuvent affecter la qualité de vie et causer d'autres problèmes de santé. Les changements et problèmes de santé, notamment les facteurs liés au système nerveux et au mode de vie, peuvent provoquer ou contribuer à l'IU chez les hommes et les femmes.

Marché des troubles de la vessie en Asie-Pacifique

Les troubles de la vessie les plus courants sont l'hyperactivité vésicale et l'incontinence urinaire. Ces problèmes sont associés au système nerveux. Les nerfs transmettent des messages du cerveau à la vessie, indiquant que les muscles se contractent ou se relâchent. Le cerveau décide du moment acceptable pour uriner, et l'incontinence urinaire peut survenir lorsqu'il y a un problème pour recevoir le message du cerveau. Des changements et des problèmes de santé peuvent entraîner l'incontinence urinaire, notamment le vieillissement, une infection de la vessie, la constipation, le diabète et le surpoids, entre autres

Le marché des troubles de la vessie en Asie-Pacifique devrait connaître une croissance du marché au cours de la période de prévision de 2022 à 2029. Data Bridge Market Research analyse que le marché croît avec un TCAC de 13,1 % au cours de la période de prévision de 2022 à 2029 et devrait atteindre 5 280,11 millions USD d'ici 2029.

Rapport métrique

Détails

Période de prévision

2022 à 2029

Année de base

2021

Années historiques

2020 (Personnalisable 2019-2014)

Unités quantitatives

Chiffre d'affaires en millions USD

Segments couverts

Par type (cystite, incontinence urinaire, vessie hyperactive, cystite interstitielle, cancer de la vessie), type de traitement (chirurgie, médicament, non chirurgical), utilisateur final (hôpitaux, cliniques, centres de chirurgie ambulatoire, autres), canal de distribution (direct, vente au détail)

Pays couverts

Chine, Japon, Inde, Corée du Sud, Australie, Singapour, Thaïlande, Malaisie, Indonésie, Philippines, Vietnam, Reste de l'Asie-Pacifique

Acteurs du marché couverts

Les principales entreprises présentes sur le marché sont Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (Une filiale de KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Gaylord Chemical Company, LLC, Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Sciences, entre autres.

Définition du marché des troubles de la vessie en Asie-Pacifique

Bladder related disorders include Cystitis - inflammation of the bladder, often from an infection, Urinary incontinence - loss of bladder control, Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time, Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination and bladder cancer.

Different tests are performed by the doctors to diagnose the bladder disorder that includes x-rays, urine tests, and a bladder wall examination by scope called cystoscope. The treatment of the disorder depends on the cause of the problem and the treatment includes medication, surgeries (in severe cases), and non-surgical procedures.

Anticholinergic medications are the first-line of pharmacotherapy in Overactive Bladder (OAB) syndrome. OAB is a clinical symptom characterized by urgency of desire to urine pass, which is difficult to defer, generally frequency to pass urine more than eight times per day are consider into OAB. Anticholinergic drugs inhibit the muscarinic receptors at the detrusor muscle that reduce the bladder contractility. To reduce the side effects, new medications with improved bladder selectivity and extended-release formulations are being developed. The majority of the more recent medications are equally effective at reducing the symptoms of an overactive bladder.

Asia-Pacific Bladder Disorders Market Dynamics

Drivers

  • STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS

Bladder disorders are a number of bladder issues that can affect daily physical activities. The most common bladder disorders are cystitis, interstitial cystitis, overactive bladder, urinary incontinence, and bladder cancer. Most bladder issues are caused by a bacterial infection that enters the urinary tract.

Various strategic initiatives by the market players in terms of collaboration, acquisition, partnership, and others, allow them to increase their company's product portfolio, leading to market expansion and hence enhancing the product demand among customers, which ultimately provides the market players to earn maximum revenue.

  • GROWING GERIATRIC POPULATION

Aging is a strong risk factor that can associate with bladder-related disorders. Aging prompts neurologic, anatomic, and biochemical changes in bladder function, which can dispose to the development of OAB and Overactive bladder is the most common problem among the geriatric population. Aging population is suffering from various bladder-associated problems and disorders due to which they are the predominant users of chronic health management services and solutions.

According to the noble study, the prevalence rate of overactive bladder is approximately 16.9 in women and men, around 16.0%, and the prevalence of OAB is growing with age. However, treatment guidelines specify the preferred first-, second-, and third-line OAB therapy strategies. Bladder disorders are associated with the Neurologic disorders such as dementia and in this age group OAB is very challenging for the senior population. Over the last few decades, the old age population has been drastically growing worldwide.

  • RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS

Nowadays, various treatment options and innovative therapies are available for OAB and other bladder disorders. Many biopharmaceutical and pharmaceutical companies are investing in various unconventional therapies for bladder disorders, which are expected to launch during the forecast period.

  • COMBINATION OF DIFFERENT TARGET THERAPIES

Combination Therapies are much more effective than monotherapy, without additional side effects. Combination Therapies are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieve patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.

Opportunities

  • SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS

Chronic diseases are considered one of the major leading causes of death in developing countries worldwide. Therefore, the importance of healthcare management of chronic management is increased among public health practitioners.

Bladder disorder management now emphasizes assisting patients with various alternatives for self-care and a range of consultation services to educate patients about their illness state and move forward. These therapies also assist patients in getting over emotional trauma and anxiety, which may act as a counter-protective mechanism.

Rising technical breakthroughs allow healthcare organizations to explore innovative services and solutions for managing chronic bladder disorders. Since they are not required to stay in the hospital for an extended period of time, they have also decreased costs and patient volume. Furthermore, lowering hospital visits and stays makes this development convenient for older adults. Considering the favorable aspects, many organizations and businesses are developing and implementing the most recent technologies in managing chronic diseases to enhance patient outcomes.

  • RISING DISEASE MANAGEMENT PROGRAMS

People with bladder-related problems typically need more medical services, such as hospital stays, doctor visits, and prescription medications. The rise in the number of people living longer with many chronic problems and increasing healthcare expenditures has encouraged better healthcare plans.

Disease management is one strategy that tries to improve care while lowering the expense of caring for the chronically ill. Programs for managing diseases aim to enhance the health of people with certain chronic disorders such as bladder disorders while lowering the demand for medical services and associated expenses for consequences that can be avoided, such as hospital stays and emergency visits. These programs also include information regarding chronic disease management services and solutions. These are becoming very popular owing to the rising prevalence of chronic diseases worldwide. Government and healthcare organizations have organized and implemented these chronic diseases with multiple disease management programs such as bladder cancer, interstitial cystitis, and overactive bladder management programs. Since disease management programs can significantly improve self-care practices and reduce hospital visits and staying periods to a more excellent extent, they receive more attention among people.

Restraints/Challenges

However, the difficulty in diagnosing the disease and the cost of the treatments and diagnostics are high due to the procedure of various checkpoints along with the high-tech technologies and modalities to perform the procedures. The cost of the procedure generally gets elevated because of the high cost of the advanced technological devices used in the treatment, which is expected to restrain the market growth.

This Asia-Pacific bladder disorders market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asia-Pacific bladder disorders market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Post COVID-19 Impact on Asia- Pacific Bladder Disorders Market

COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world's population. Hence, the pandemic has effected positively on this market

Recent Development

  • In April, Axonics, Inc. announced the comprehensive launch of the Axonics F15 across the U.S., which is developing and commercializing novel products to treat bladder and bowel dysfunction. This launch by the company has increased its product portfolio, leading to increased sales and demand in the future.

Asia-Pacific Bladder Disorders Market Scope

Asia-Pacific bladder disorders market is segmented into type, treatment type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Type

On the basis of type, the Asia-Pacific bladder disorders market is segmented into cystitis, urinary incontinence, overactive bladder, interstitial cystitis, and bladder cancer.

Treatment type

  • Surgery
  • Medications
  • Others

On the basis of product, the Asia-Pacific bladder disorders market is segmented into surgery, medication, and others.

End User

  • Hospital
  • Clinics
  • Ambulatory Surgery centers
  • Others

On the basis of end users, the Asia-Pacific bladder disorders market is segmented into hospitals, clinics, ambulatory surgery centers, and others.

Distribution Channel

  • Direct
  • Retail

Marché des troubles de la vessie

On the basis of distribution channel, the Asia-Pacific bladder disorders market is segmented into direct and retail.

Asia-Pacific Bladder Disorders Market Regional Analysis/Insights    

Asia-Pacific bladder disorders market is analyzed, and market size insights and trends are provided by country, type, treatment type, end user, and distribution channel, as referenced above.

Countries covered in this market are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific.

China dominates the Asia-Pacific bladder disorders market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of overactive bladder disorder in the region, and growing R&D investments and the launch of novel therapies are boosting the market

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Asia-Pacific brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Asia-Pacific Bladder Disorders Market Share Analysis

Le paysage concurrentiel du marché des troubles de la vessie en Asie-Pacifique fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Asie-Pacifique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus ne concernent que l'orientation de l'entreprise vers le marché des troubles de la vessie en Asie-Pacifique.

Français Certains des principaux acteurs opérant sur le marché des troubles de la vessie en Asie-Pacifique sont Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (Une filiale de KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Gaylord Chemical Company, LLC, Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Sciences, entre autres.

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des parts de marché des entreprises, les normes de mesure, l'APAC par rapport aux régions et l'analyse des parts des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.

Personnalisation disponible

Data Bridge Market Research est un leader dans la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, le marché des produits remis à neuf et une analyse de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC BLADDER DISORDERS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S FIVE FORCES

4.3 ASIA PACIFIC BLADDER DISORDERS MARKET, PIPELINE ANALYSIS

5 ASIA PACIFIC BLADDER DISORDER MARKET: REGULATIONS

5.1 THE U.S. REGULATORY FRAMEWORK FOR BLADDER DISOREDER MEDICATION

5.2 EUROPE REGULATORY FRAMEWORK FOR BLADDER DISORDER DRUGS

5.3 JAPAN REGULATORY GUIDANCE ON BLADDER DISORDER DRUGS

6 ASIA PACIFIC BLADDER DISORDERS MARKET OVERVIEW

6.1 DRIVERS

6.1.1 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS

6.1.2 GROWING GERIATRIC POPULATION

6.1.3 RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS

6.1.4 COMBINATION OF DIFFERENT TARGET THERAPIES

6.2 RESTRAINTS

6.2.1 HIGH COST ASSOCIATED WITH BLADDER DISORDER DIAGNOSTIC TREATMENT

6.2.2 PRODUCTS RECALLS FROM MARKET

6.3 OPPORTUNITIES

6.3.1 SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS

6.3.2 RISING DISEASE MANAGEMENT PROGRAMS

6.4 CHALLENGES

6.4.1 LACK OF AWARENESS ABOUT BLADDER DISORDERS RELATED PROBLEMS

6.4.2 PATENT EXPIRY OF DRUGS

7 ASIA PACIFIC BLADDER DISORDERS MARKET, BY TYPE

7.1 OVERVIEW

7.2 OVERACTIVE BLADDER

7.3 URINARY INCONTINENCE

7.4 CYSTITIS

7.5 INTERSTITIAL CYSTITIS

7.6 BLADDER CANCER

7.7 OTHERS

8 ASIA PACIFIC BLADDER DISORDERS MARKET, BY TREATMENT TYPE

8.1 OVERVIEW

8.2 MEDICATION

8.2.1 TOLTERODINE

8.2.2 MIRABEGRON

8.2.3 FESOTERODINE

8.2.4 OXYBUTYNIN

8.2.5 SOLIFENACIN

8.2.6 DARIFENACIN

8.2.7 TROSPIUM

8.2.8 OTHERS

8.3 SURGERY

8.3.1 SURGERY TO INCREASE BLADDER CAPACITY

8.3.2 BLADDER REMOVAL

8.3.3 OTHERS

8.4 OTHERS

9 ASIA PACIFIC BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW

9.2 DIRECT

9.3 RETAIL

10 ASIA PACIFIC BLADDER DISORDERS MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.3 CLINICS

10.4 AMBULATORY SURGICAL CENTERS

10.5 OTHERS

11 ASIA PACIFIC BLADDER DISORDERS MARKET, BY GEOGRAPHY

11.1 ASIA-PACIFIC

11.1.1 CHINA

11.1.2 JAPAN

11.1.3 INDIA

11.1.4 AUSTRALIA

11.1.5 SOUTH KOREA

11.1.6 THAILAND

11.1.7 SINGAPORE

11.1.8 INDONESIA

11.1.9 MALAYSIA

11.1.10 VIETNAM

11.1.11 PHILIPPINES

11.1.12 REST OF ASIA-PACIFIC

12 ASIA PACIFIC BLADDER DISORDERS MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 MERCK AND CO. INC. (2021)

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENT

14.2 ASTELLAS PHARMA INC. (2021)

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 BRISTOL-MYERS SQUIBB COMPANY (2021)

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENT

14.4 BOSTON SCIENTIFIC CORPORATION (2021)

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.5 VIATRIS INC. (2021)

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENT

14.6 ABBVIE (2021)

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENT

14.7 AXONICS, INC. (2021)

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENT

14.8 BLUE WIND MEDICAL (2021)

14.8.1 COMPANY SNAPSHOT

14.8.2 PRODUCT PORTFOLIO

14.8.3 RECENT DEVELOPMENT

14.9 COLOPLAST CORP. (2021)

14.9.1 COMPANY SNAPSHOT

14.9.2 REVENUE ANALYSIS

14.9.3 PRODUCT PORTFOLIO

14.1 GAYLORD CHEMICAL COMPANY, LLC (2021)

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENT

14.11 JOHNSON & JOHNSON SERVICES, INC. (2021)

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.12 KYORIN PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF KYORIN HOLDINGS, INC.) (2021)

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 LABORIE (2021)

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 MEDTRONIC (2021)

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENTS

14.15 PFIZER INC. (2021)

14.15.1 COMPANY SNAPSHOT

14.15.2 REVENUE ANALYSIS

14.15.3 PRODUCT PORTFOLIO

14.15.4 RECENT DEVELOPMENTS

14.16 VALENCIA TECHNOLOGIES (2021)

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENT

14.17 SUN PHAMACEUTICAL INDUSTRIES LTD. (2021)

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENT

14.18 SWATI SPENTOSE (2021)

14.18.1 COMPANY SNAPSHOT

14.18.2 PRODUCT PORTFOLIO

14.18.3 RECENT DEVELOPMENT

14.19 UROVANT SCIENCES (2021)

14.19.1 COMPANY SNAPSHOT

14.19.2 PRODUCT PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.2 ZYDUS GROUP (2021)

14.20.1 COMPANY SNAPSHOT

14.20.2 PRODUCT PORTFOLIO

14.20.3 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

Liste des tableaux

TABLE 1 ASIA PACIFIC BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 2 ASIA PACIFIC OVERACTIVE BLADDER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 ASIA PACIFIC URINARY INCONTINENCE IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 ASIA PACIFIC INTERSTITIAL CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC BLADDER CANCER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC MEDICATION IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC SURGERY IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC DIRECT IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC RETAIL IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC HOSPITALS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 ASIA PACIFIC CLINICS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 ASIA PACIFIC OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 23 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 24 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 25 ASIA-PACIFIC MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 26 ASIA-PACIFIC SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 27 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 29 CHINA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 30 CHINA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 31 CHINA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 32 CHINA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 33 CHINA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 CHINA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 35 JAPAN BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 36 JAPAN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 37 JAPAN MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 38 JAPAN SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 39 JAPAN BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 40 JAPAN BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 41 INDIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 42 INDIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 43 INDIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 44 INDIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 45 INDIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 46 INDIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 47 AUSTRALIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 AUSTRALIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 49 AUSTRALIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 50 AUSTRALIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 51 AUSTRALIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 AUSTRALIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 53 SOUTH KOREA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 SOUTH KOREA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 55 SOUTH KOREA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 56 SOUTH KOREA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 57 SOUTH KOREA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 58 SOUTH KOREA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 59 THAILAND BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 THAILAND BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 61 THAILAND MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 62 THAILAND SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 63 THAILAND BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 THAILAND BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 65 SINGAPORE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 SINGAPORE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 67 SINGAPORE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 68 SINGAPORE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 69 SINGAPORE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 70 SINGAPORE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 71 INDONESIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 INDONESIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 73 INDONESIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 74 INDONESIA. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 75 INDONESIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 76 INDONESIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 77 MALAYSIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 78 MALAYSIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 79 MALAYSIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 80 MALAYSIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 81 MALAYSIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 82 MALAYSIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 83 VIETNAM BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 84 VIETNAM BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 85 VIETNAM MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 86 VIETNAM SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 87 VIETNAM BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 88 VIETNAM BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 89 PHILIPPINES BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 90 PHILIPPINES BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 91 PHILIPPINES MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 92 PHILIPPINES SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 93 PHILIPPINES BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 94 PHILIPPINES BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 95 REST OF ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

Liste des figures

FIGURE 1 ASIA PACIFIC BLADDER DISORDERS MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC BLADDER DISORDERS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC BLADDER DISORDERS MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC BLADDER DISORDERS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC BLADDER DISORDERS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC BLADDER DISORDERS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC BLADDER DISORDERS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC BLADDER DISORDERS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 ASIA PACIFIC BLADDER DISORDERS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC BLADDER DISORDERS MARKET: SEGMENTATION

FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF BLADDER DISORDERS EXPECTED TO DRIVE THE ASIA PACIFIC BLADDER DISORDERS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 OVERACTIVE BLADDER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC BLADDER DISORDERS MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC BLADDER DISORDER MARKET

FIGURE 14 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TYPE, 2021

FIGURE 15 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 16 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 17 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2021

FIGURE 19 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)

FIGURE 20 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)

FIGURE 21 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 22 ASIA PACIFIC BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 23 ASIA PACIFIC BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 24 ASIA PACIFIC BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 25 ASIA PACIFIC BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 26 ASIA PACIFIC BLADDER DISORDERS MARKET: BY END USER, 2021

FIGURE 27 ASIA PACIFIC BLADDER DISORDERS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 28 ASIA PACIFIC BLADDER DISORDERS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 ASIA PACIFIC BLADDER DISORDERS MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 ASIA-PACIFIC BLADDER DISORDERS MARKET: SNAPSHOT (2021)

FIGURE 31 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2021)

FIGURE 32 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 33 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 34 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY TYPE (2022-2029)

FIGURE 35 ASIA PACIFIC BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The Asia-Pacific Bladder Disorders Market value is expected USD 5,280.11 million by 2029.
The Asia-Pacific Bladder Disorders Market is to grow at a CAGR of 13.1% during the forecast by 2029.
By Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical), End User (Hospitals, Clinics, Ambulatory Surgery Centers, Others), Distribution Channel (Direct, Retail) are covered in this report.
The major countries covered in the Asia-Pacific Bladder Disorders Market are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.